AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis

Documenti analoghi

• CD28 Homodimer Interface Mimetic Peptide Acts as a Preventive and Therapeutic Agent in Models of Severe Bacterial Sepsis and Gram-Negative Bacterial Peritonitis
  di: Ramachandran, Girish, et al.
  Pubblicazione: (2015)
• Single Administration of p2TA (AB103), a CD28 Antagonist Peptide, Prevents Inflammatory and Thrombotic Reactions and Protects against Gastrointestinal Injury in Total-Body Irradiated Mice
  di: Mirzoeva, Salida, et al.
  Pubblicazione: (2014)
• A Peptide Antagonist of CD28 Signaling Attenuates Toxic Shock and Necrotizing Soft-Tissue Infection Induced by Streptococcus pyogenes
  di: Ramachandran, Girish, et al.
  Pubblicazione: (2013)
• p28 Bacterial Peptide, as an Anticancer Agent
  di: Yaghoubi, Atieh, et al.
  Pubblicazione: (2020)
• Influence of severity of illness on the effects of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis
  di: Opal, SM, et al.
  Pubblicazione: (2009)